lemofloxacin (CAS 98079-51-7)

Lemofloxacin, a fluoroquinolone antibiotic, exerts its antimicrobial activity by targeting bacterial DNA gyrase and topoisomerase IV enzymes, crucial for DNA replication, transcription, and repair. By binding to the DNA gyrase complex, Lemofloxacin inhibits its activity, leading to the formation of double-stranded DNA breaks and ultimately bacterial cell death. Research has extensively investigated its efficacy against a broad spectrum of Gram-positive and Gram-negative bacteria, including strains resistant to other antibiotics. Additionally, Lemofloxacin has been utilized as a tool in microbiology research to explain the structure-activity relationships of fluoroquinolone antibiotics, investigate mechanisms of bacterial resistance, and explore strategies for improving antibiotic efficacy and combating multidrug-resistant bacterial infections. Furthermore, studies have explored its potential in combination therapy regimens to enhance antibacterial activity or overcome resistance mechanisms. Its unique mechanism of action and potent antimicrobial properties make Lemofloxacin a valuable asset in antimicrobial research, offering insights into bacterial DNA replication and repair processes and providing a basis for the development of novel antibiotics with enhanced efficacy and reduced resistance profiles.